{"transactions":[{"id":1725405,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T17:31:13.000Z","date":"2023-11-30","kind":"sale","planned":false,"acquired":false,"shares":14934,"price":0.8581,"value":12814.8654,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.85 to $0.9261, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":251522,"source":{"system":"sec-edgar","filing":"0001209191-23-057049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123057049/doc4.xml","form_type":"4"}},{"id":1725404,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T17:31:13.000Z","date":"2023-11-29","kind":"sale","planned":false,"acquired":false,"shares":3131,"price":0.906,"value":2836.686,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":266456,"source":{"system":"sec-edgar","filing":"0001209191-23-057049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123057049/doc4.xml","form_type":"4"}},{"id":1725403,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T17:31:13.000Z","date":"2023-11-30","kind":"sale","planned":false,"acquired":false,"shares":108145,"price":0.8581,"value":92799.2245,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.85 to $0.9261, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1821483,"source":{"system":"sec-edgar","filing":"0001209191-23-057049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123057049/doc4.xml","form_type":"4"}},{"id":1725402,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T17:31:13.000Z","date":"2023-11-29","kind":"sale","planned":false,"acquired":false,"shares":22674,"price":0.906,"value":20542.644,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1929628,"source":{"system":"sec-edgar","filing":"0001209191-23-057049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123057049/doc4.xml","form_type":"4"}},{"id":1731205,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-23T00:45:34.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":236,"price":0.9014,"value":212.7304,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.903, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":269587,"source":{"system":"sec-edgar","filing":"0001209191-23-056548","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056548/doc4.xml","form_type":"4"}},{"id":1731204,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-23T00:45:34.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":1707,"price":0.9014,"value":1538.6898,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.903, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1952302,"source":{"system":"sec-edgar","filing":"0001209191-23-056548","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056548/doc4.xml","form_type":"4"}},{"id":1734483,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:31:40.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":3792,"price":0.92,"value":3488.64,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":269823,"source":{"system":"sec-edgar","filing":"0001209191-23-056185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056185/doc4.xml","form_type":"4"}},{"id":1734482,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:31:40.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":1134,"price":0.93,"value":1054.62,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":273615,"source":{"system":"sec-edgar","filing":"0001209191-23-056185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056185/doc4.xml","form_type":"4"}},{"id":1734481,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:31:40.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":1040,"price":0.96,"value":998.4,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":274749,"source":{"system":"sec-edgar","filing":"0001209191-23-056185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056185/doc4.xml","form_type":"4"}},{"id":1734480,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:31:40.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":27465,"price":0.92,"value":25267.8,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1954009,"source":{"system":"sec-edgar","filing":"0001209191-23-056185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056185/doc4.xml","form_type":"4"}},{"id":1734479,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:31:40.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":8211,"price":0.93,"value":7636.23,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1981474,"source":{"system":"sec-edgar","filing":"0001209191-23-056185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056185/doc4.xml","form_type":"4"}},{"id":1734478,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:31:40.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":7531,"price":0.96,"value":7229.76,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price.  These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1989685,"source":{"system":"sec-edgar","filing":"0001209191-23-056185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123056185/doc4.xml","form_type":"4"}},{"id":1855886,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T21:13:02.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":1.63,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-037100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123037100/doc4.xml","form_type":"4"}},{"id":2235882,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T22:11:54.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the \"Vesting Commencement Date\") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":1.99,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-036075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919122036075/doc4.xml","form_type":"4"}},{"id":2316623,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-28T19:21:20.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the \"Vesting Commencement Date\") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":3.03,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-012462","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000089924322012462/doc4.xml","form_type":"4"}},{"id":2871887,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":5655,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":5655},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871886,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C- 2 Preferred Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":47718,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47718},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871885,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C- 1 Preferred Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":43901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43901},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871884,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":150802,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150802},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871883,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":40953,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":40953},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871882,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C- 2 Preferred Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":345568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":345568},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871881,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C- 1 Preferred Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":317922,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317922},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871880,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1092080,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1092080},"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871879,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":24267,"price":20,"value":485340.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":275789,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871878,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":20,"price":20,"value":400.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Upon closing of the Issuer's IPO, Vivo Capital Surplus Fund VIII, L.P. exercised a warrant to purchase 5,655 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Surplus Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 20 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Surplus Fund VIII, L.P. the remaining 5,635 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":251522,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871877,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":5655,"price":0.07,"value":395.85,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":251542,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871876,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":47718,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":245887,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871875,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":43901,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":198169,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871874,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":150802,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":154268,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871873,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":175733,"price":20,"value":3514660.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1997216,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871872,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":144,"price":20,"value":2880.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Upon closing of the Issuer's IPO, Vivo Capital Fund VIII, L.P. exercised a warrant to purchase 40,953 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 144 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Fund VIII, L.P. the remaining 40,809 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1821483,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871871,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":40953,"price":0.07,"value":2866.71,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1821627,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871870,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":345568,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1780674,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871869,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":317922,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1435106,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":2871868,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:25:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1092080,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of three voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein."}],"balance_after":1117184,"source":{"system":"sec-edgar","filing":"0001209191-21-008744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121008744/doc4.xml","form_type":"4"}},{"id":4072161,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-02-08T01:10:21.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":5068,"price":1.7263,"value":8748.8884,"ownership":{"direct":false,"nature":"See\nfootnotes"},"footnotes":[{"field":"date","element":"transactionDate","label":"F5","text":"Resigned from the Board of Directors effective December 31, 2017. Fees incurred for 2017 Board and Committee Services."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018, or $1.7263."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund except to the extent of any pecuniary interest therein."}],"balance_after":4027292,"source":{"system":"sec-edgar","filing":"0000899243-18-003165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924318003165/doc4.xml","form_type":"4"}},{"id":4126408,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2017-12-20T02:55:39.000Z","date":"2017-12-15","kind":"purchase","acquired":true,"shares":9318,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The securities are held directly by Vivo Ventures V Affiliates Fund L.P. (\"Vivo Ventures V Affiliates Fund\"). Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such securities. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures V Affiliates Fund. Edgar Engleman, Albert Cha and Frank Kung are members of Vivo V LLC and disclaim beneficial ownership of the securities held by Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities are included within 12,592 units purchased by Vivo Ventures V Affiliates Fund for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrant has a term of three years and, in the event of positive Phase III results for Diazoxide Choline Controlled-Release (DCCR) tablet in Prader-Willi syndrome (PWS), the warrant will expire 30 days from the announcement of such results."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund II, L.P (\"BDF II Fund\"), Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (\"BDF IV Funds\"). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund. BioAsia Management LLC is the general partner of BDF II Fund and may be deemed to beneficially own the common stock of Issuer owned by BDF II Fund. BioAsia Investments IV, LLC (\"BAI IV\") is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by BDF IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) BioAsia Management LLC, BAI IV and Vivo V LLC each disclaims beneficial ownership of the common stock of Issuer held by each of BDF II Fund, BDF IV Funds, Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund respectively, except to the extent of its pecuniary interest therein. Edgar Engleman, Frank Kung and Anselm Leung are the voting members of BioAsia Management LLC, Edgar Engleman and Frank Kung are the voting members of BAI IV, and Edgar Engleman, Frank Kung and Albert Cha are the voting members of Vivo V LLC and they disclaim beneficial ownership of the securities held by BDF II Fund, BDF IV Funds, Vivo Ventures Fund V or the Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."}],"balance_after":9318,"derivative":{"exercise_price":2,"exercise_date":"2017-12-15","underlying":"Common Stock","underlying_shares":9318},"source":{"system":"sec-edgar","filing":"0000899243-17-029271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317029271/doc4.xml","form_type":"4"}},{"id":4126407,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2017-12-20T02:55:39.000Z","date":"2017-12-15","kind":"purchase","acquired":true,"shares":793937,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities are held directly by Vivo Ventures Fund V. L.P. (\"Vivo Ventures Fund V\"). Vivo Ventures V, LLC (\"Vivo V LLC\") is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such securities. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V.  Edgar Engleman, Albert Cha and Frank Kung are members of Vivo V LLC and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities are included within 1,072,888 units purchased by Vivo Ventures Fund V for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrant has a term of three years and, in the event of positive Phase III results for Diazoxide Choline Controlled-Release (DCCR) tablet in Prader-Willi syndrome (PWS), the warrant will expire 30 days from the announcement of such results."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund II, L.P (\"BDF II Fund\"), Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (\"BDF IV Funds\"). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund. BioAsia Management LLC is the general partner of BDF II Fund and may be deemed to beneficially own the common stock of Issuer owned by BDF II Fund. BioAsia Investments IV, LLC (\"BAI IV\") is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by BDF IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) BioAsia Management LLC, BAI IV and Vivo V LLC each disclaims beneficial ownership of the common stock of Issuer held by each of BDF II Fund, BDF IV Funds, Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund respectively, except to the extent of its pecuniary interest therein. Edgar Engleman, Frank Kung and Anselm Leung are the voting members of BioAsia Management LLC, Edgar Engleman and Frank Kung are the voting members of BAI IV, and Edgar Engleman, Frank Kung and Albert Cha are the voting members of Vivo V LLC and they disclaim beneficial ownership of the securities held by BDF II Fund, BDF IV Funds, Vivo Ventures Fund V or the Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."}],"balance_after":793937,"derivative":{"exercise_price":2,"exercise_date":"2017-12-15","underlying":"Common Stock","underlying_shares":793937},"source":{"system":"sec-edgar","filing":"0000899243-17-029271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317029271/doc4.xml","form_type":"4"}},{"id":4126406,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T02:55:39.000Z","date":"2017-12-15","kind":"purchase","acquired":true,"shares":12592,"price":1.8425,"value":23200.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The securities are held directly by Vivo Ventures V Affiliates Fund L.P. (\"Vivo Ventures V Affiliates Fund\"). Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such securities. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures V Affiliates Fund. Edgar Engleman, Albert Cha and Frank Kung are members of Vivo V LLC and disclaim beneficial ownership of the securities held by Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund II, L.P (\"BDF II Fund\"), Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (\"BDF IV Funds\"). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund. BioAsia Management LLC is the general partner of BDF II Fund and may be deemed to beneficially own the common stock of Issuer owned by BDF II Fund. BioAsia Investments IV, LLC (\"BAI IV\") is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by BDF IV Funds."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"(Continued from Footnote 6) BioAsia Management LLC, BAI IV and Vivo V LLC each disclaims beneficial ownership of the common stock of Issuer held by each of BDF II Fund, BDF IV Funds, Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund respectively, except to the extent of its pecuniary interest therein. Edgar Engleman, Frank Kung and Anselm Leung are the voting members of BioAsia Management LLC, Edgar Engleman and Frank Kung are the voting members of BAI IV, and Edgar Engleman, Frank Kung and Albert Cha are the voting members of Vivo V LLC and they disclaim beneficial ownership of the securities held by BDF II Fund, BDF IV Funds, Vivo Ventures Fund V or the Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund II, L.P (\"BDF II Fund\"), Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (\"BDF IV Funds\"). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund. BioAsia Management LLC is the general partner of BDF II Fund and may be deemed to beneficially own the common stock of Issuer owned by BDF II Fund. BioAsia Investments IV, LLC (\"BAI IV\") is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by BDF IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) BioAsia Management LLC, BAI IV and Vivo V LLC each disclaims beneficial ownership of the common stock of Issuer held by each of BDF II Fund, BDF IV Funds, Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund respectively, except to the extent of its pecuniary interest therein. Edgar Engleman, Frank Kung and Anselm Leung are the voting members of BioAsia Management LLC, Edgar Engleman and Frank Kung are the voting members of BAI IV, and Edgar Engleman, Frank Kung and Albert Cha are the voting members of Vivo V LLC and they disclaim beneficial ownership of the securities held by BDF II Fund, BDF IV Funds, Vivo Ventures Fund V or the Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."}],"balance_after":4033540,"source":{"system":"sec-edgar","filing":"0000899243-17-029271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317029271/doc4.xml","form_type":"4"}},{"id":4126405,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T02:55:39.000Z","date":"2017-12-15","kind":"purchase","acquired":true,"shares":1072888,"price":1.8425,"value":1976796.14,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities are held directly by Vivo Ventures Fund V. L.P. (\"Vivo Ventures Fund V\"). Vivo Ventures V, LLC (\"Vivo V LLC\") is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such securities. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V.  Edgar Engleman, Albert Cha and Frank Kung are members of Vivo V LLC and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund II, L.P (\"BDF II Fund\"), Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (\"BDF IV Funds\"). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund. BioAsia Management LLC is the general partner of BDF II Fund and may be deemed to beneficially own the common stock of Issuer owned by BDF II Fund. BioAsia Investments IV, LLC (\"BAI IV\") is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by BDF IV Funds."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"(Continued from Footnote 6) BioAsia Management LLC, BAI IV and Vivo V LLC each disclaims beneficial ownership of the common stock of Issuer held by each of BDF II Fund, BDF IV Funds, Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund respectively, except to the extent of its pecuniary interest therein. Edgar Engleman, Frank Kung and Anselm Leung are the voting members of BioAsia Management LLC, Edgar Engleman and Frank Kung are the voting members of BAI IV, and Edgar Engleman, Frank Kung and Albert Cha are the voting members of Vivo V LLC and they disclaim beneficial ownership of the securities held by BDF II Fund, BDF IV Funds, Vivo Ventures Fund V or the Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund II, L.P (\"BDF II Fund\"), Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (\"BDF IV Funds\"). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund. BioAsia Management LLC is the general partner of BDF II Fund and may be deemed to beneficially own the common stock of Issuer owned by BDF II Fund. BioAsia Investments IV, LLC (\"BAI IV\") is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by BDF IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) BioAsia Management LLC, BAI IV and Vivo V LLC each disclaims beneficial ownership of the common stock of Issuer held by each of BDF II Fund, BDF IV Funds, Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund respectively, except to the extent of its pecuniary interest therein. Edgar Engleman, Frank Kung and Anselm Leung are the voting members of BioAsia Management LLC, Edgar Engleman and Frank Kung are the voting members of BAI IV, and Edgar Engleman, Frank Kung and Albert Cha are the voting members of Vivo V LLC and they disclaim beneficial ownership of the securities held by BDF II Fund, BDF IV Funds, Vivo Ventures Fund V or the Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein."}],"balance_after":4020948,"source":{"system":"sec-edgar","filing":"0000899243-17-029271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317029271/doc4.xml","form_type":"4"}},{"id":4192128,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-04T22:03:49.000Z","date":"2017-10-02","kind":"grant","acquired":true,"shares":16827,"price":0.52,"value":8750.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on September 29, 2017, or $0.52."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund except to the extent of any pecuniary interest therein."}],"balance_after":14695186,"source":{"system":"sec-edgar","filing":"0000899243-17-023579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317023579/doc4.xml","form_type":"4"}},{"id":4256408,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-18T00:58:39.000Z","date":"2017-07-06","kind":"grant","acquired":true,"shares":14344,"price":0.61,"value":8749.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or $0.61."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund except to the extent of any pecuniary interest therein."}],"balance_after":14666954,"source":{"system":"sec-edgar","filing":"0000899243-17-018369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317018369/doc4.xml","form_type":"4"}},{"id":4328251,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2017-05-09T20:34:38.000Z","date":"2017-05-08","kind":"grant","acquired":true,"shares":45139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is May 8, 2017) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier."}],"balance_after":45139,"derivative":{"exercise_price":0.72,"expiration_date":"2027-05-08","underlying":"Common Stock","underlying_shares":45139},"source":{"system":"sec-edgar","filing":"0000899243-17-012479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317012479/doc4.xml","form_type":"4"}},{"id":4352035,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-14T10:09:19.000Z","date":"2017-04-07","kind":"grant","acquired":true,"shares":13888,"price":0.63,"value":8749.44,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Effective January 1, 2017, annual board and committee cash retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis which is payable directly to Vivo Capital LLC for the service of Edgar Engleman, M.D. These shares were issued in lieu of cash in the amount of $8,750, as compensation for Edgar Engleman's services as a board member of the Issuer pursuant to Rule 16b-3(d) and are held of record by Vivo Capital LLC. Vivo Capital LLC, an investment adviser registered with the Securities Exchange Commission, provides investment management, administrative and other related services to Vivo Ventures V, LLC, Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. Vivo Ventures V, LLC is the sole general partner of Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. Edgar Engleman is a managing member of Vivo Capital LLC and a managing member of Vivo Ventures V, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on April 7, 2017, or $0.63."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund  except to the extent of any pecuniary interest therein."}],"balance_after":14652610,"source":{"system":"sec-edgar","filing":"0000899243-17-010291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317010291/doc4.xml","form_type":"4"}},{"id":4352034,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-14T10:09:19.000Z","date":"2017-03-07","kind":"purchase","acquired":true,"shares":16303,"price":0.96,"value":15650.88,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares are held directly by Vivo Ventures V Affiliates Fund L.P. (\"Vivo Ventures V Affiliates Fund\"). Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund  except to the extent of any pecuniary interest therein."}],"balance_after":14638722,"source":{"system":"sec-edgar","filing":"0000899243-17-010291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317010291/doc4.xml","form_type":"4"}},{"id":4352033,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-14T10:09:19.000Z","date":"2017-03-07","kind":"purchase","acquired":true,"shares":902,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares are held directly by Vivo Ventures V Affiliates Fund L.P. (\"Vivo Ventures V Affiliates Fund\"). Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in a private transaction from a former shareholder of Essentialis in exchange for cash to be used to satisfy certain withholding obligations of the shareholder, based on the closing price per share of Issuer common stock on March 7, 2017 of $0.68."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund  except to the extent of any pecuniary interest therein."}],"balance_after":14622419,"source":{"system":"sec-edgar","filing":"0000899243-17-010291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317010291/doc4.xml","form_type":"4"}},{"id":4352032,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-14T10:09:19.000Z","date":"2017-03-07","kind":"grant","acquired":true,"shares":66934,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares are held directly by Vivo Ventures V Affiliates Fund L.P. (\"Vivo Ventures V Affiliates Fund\"). Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired on March 7, 2017, as consideration for the reporting person(s) common stock of Essentialis, Inc. (\"Essentialis\"), which was acquired by the Issuer, through a merger of a wholly-owned subsidiary of Issuer with and into Essentialis on March 7, 2017 pursuant to the Agreement and Plan of Merger dated December 22, 2016, by and among the Issuer, Merger Sub (as defined in the Merger Agreement), Essentialis and the Stockholders Representative (as defined therein) (the \"Merger Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund  except to the extent of any pecuniary interest therein."}],"balance_after":14621517,"source":{"system":"sec-edgar","filing":"0000899243-17-010291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317010291/doc4.xml","form_type":"4"}},{"id":4352031,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-14T10:09:19.000Z","date":"2017-03-07","kind":"purchase","acquired":true,"shares":1394158,"price":0.96,"value":1338391.68,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares are held directly by Vivo Ventures Fund V L.P. (\"Vivo Ventures Fund V\"). Vivo Ventures V LLC (Vivo V LLC) is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund  except to the extent of any pecuniary interest therein."}],"balance_after":14554583,"source":{"system":"sec-edgar","filing":"0000899243-17-010291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317010291/doc4.xml","form_type":"4"}},{"id":4352030,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-14T10:09:19.000Z","date":"2017-03-07","kind":"purchase","acquired":true,"shares":76850,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares are held directly by Vivo Ventures Fund V L.P. (\"Vivo Ventures Fund V\"). Vivo Ventures V LLC (Vivo V LLC) is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in a private transaction from a former shareholder of Essentialis in exchange for cash to be used to satisfy certain withholding obligations of the shareholder, based on the closing price per share of Issuer common stock on March 7, 2017 of $0.68."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund  except to the extent of any pecuniary interest therein."}],"balance_after":13160425,"source":{"system":"sec-edgar","filing":"0000899243-17-010291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317010291/doc4.xml","form_type":"4"}},{"id":4352029,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-14T10:09:19.000Z","date":"2017-03-07","kind":"grant","acquired":true,"shares":5683132,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares are held directly by Vivo Ventures Fund V L.P. (\"Vivo Ventures Fund V\"). Vivo Ventures V LLC (Vivo V LLC) is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired on March 7, 2017, as consideration for the reporting person(s) common stock of Essentialis, Inc. (\"Essentialis\"), which was acquired by the Issuer, through a merger of a wholly-owned subsidiary of Issuer with and into Essentialis on March 7, 2017 pursuant to the Agreement and Plan of Merger dated December 22, 2016, by and among the Issuer, Merger Sub (as defined in the Merger Agreement), Essentialis and the Stockholders Representative (as defined therein) (the \"Merger Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held directly by Vivo Ventures Fund V, Vivo Ventures V Affiliates Fund, Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds). Vivo V LLC is the sole general partner of Vivo Ventures Fund V and Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. Vivo V LLC holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. BioAsia Investments IV, LLC (BAI IV) is the sole general partner of BDF IV Funds and may be deemed to beneficially own the common stock of Issuer owned by the BDF IV Funds. BAI IV disclaims beneficial ownership of the common stock of Issuer held by each of the BDF IV Funds, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Mr. Engleman , Frank Kung and Albert Cha are members of the Vivo V LLC and BAI IV management companies and disclaims beneficial ownership of the securities held by Vivo Ventures Fund V , the BDF IV Funds, or the Vivo Ventures V Affiliates Fund  except to the extent of any pecuniary interest therein."}],"balance_after":13083575,"source":{"system":"sec-edgar","filing":"0000899243-17-010291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924317010291/doc4.xml","form_type":"4"}},{"id":4352514,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-13T19:12:51.000Z","date":"2017-04-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over 12 months measured from April 12, 2017 subject to Reporting Person's continuous service status as of each such date."}],"balance_after":10000,"derivative":{"exercise_price":8.5,"expiration_date":"2027-04-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-026944","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1305253/000120919117026944/doc4.xml","form_type":"4"}},{"id":4602486,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":107827,"kind":"person","name":"ENGLEMAN EDGAR","position":1,"cik":"0001227162","reported_name":"ENGLEMAN EDGAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-15T17:39:07.000Z","date":"2016-03-28","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant was approved by Issuer's board of directors on March 28, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the \"Plan\") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016."}],"balance_after":25000,"derivative":{"exercise_price":15.75,"expiration_date":"2026-03-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-16-141638","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1305253/000120919116141638/doc4a.xml","form_type":"4/A","original_submission_date":"2016-04-04"}}]}